{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:20:10Z","timestamp":1778001610082,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100024150","name":"Sanwa Kagaku Kenkyusho Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Secondary hyperparathyroidism (SHPT) is a complication prevalent among patients undergoing hemodialysis (HD). Upacicalcet, a novel intravenous calcimimetic agent, has demonstrated efficacy in improving bone turnover by suppressing PTH production. However, the influence of baseline bone metabolism on the efficacy of calcimimetics remains unclear. Therefore, we aimed to evaluate the efficacy of upacicalcet on PTH suppression and changes in bone turnover based on bone-specific alkaline phosphatase (BAP) levels. This study involved a post-hoc analysis of data from a phase 3, placebo-controlled, double-blind trial evaluating the effect of upacicalcet in HD patients with SHPT. Patients were categorized into 3 groups based on tertiles of baseline serum BAP levels. Key biomarkers, including serum levels of intact PTH (iPTH), BAP, tartrate-resistant acid phosphatase-5b (TRACP-5b), and BAP\/TRACP-5b ratio, were measured. Percentage changes from baseline in these parameters were assessed using a mixed-effects model for repeated measures. Additionally, cases of increased serum BAP levels following upacicalcet administration were investigated. A total of 103 HD patients with SHPT treated with upacicalcet were included in the analysis. Patients were categorized into low BAP (&amp;lt;12.8\u00a0\u03bcg\/L), medium BAP (12.8-18.8\u00a0\u03bcg\/L), and high BAP (&amp;gt;18.8\u00a0\u03bcg\/L) groups. After 24\u00a0wk of upacicalcet intervention, iPTH levels decreased across all baseline BAP groups. Serum BAP and TRACP-5b levels decreased, whereas the BAP\/TRACP-5b ratio increased across all groups. However, 26 (27.4%) patients exhibited increased BAP levels at week 24 relative to the levels at baseline despite the significant reduction in PTH levels. Upacicalcet treatment reduced PTH levels in HD patients with SHPT, regardless of baseline BAP levels. The concurrent increase in the BAP\/TRACP-5b ratio with upacicalcet suggests that this agent may exert direct effects on bone metabolism, in addition to its role in suppressing parathyroid activity.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf139","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:23:40Z","timestamp":1756380220000},"source":"Crossref","is-referenced-by-count":2,"title":["Impact of upacicalcet on bone metabolism in hemodialysis patients with secondary hyperparathyroidism: a post-hoc analysis"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8279-2966","authenticated-orcid":false,"given":"Suguru","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences , Niigata 951-8510,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Sanwa Kagaku Kenkyusho Co., Ltd. , Nagoya 461-8631,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2757-9898","authenticated-orcid":false,"given":"Hisami","family":"Yasuzawa","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Sanwa Kagaku Kenkyusho Co., Ltd. , Nagoya 461-8631,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichiro James","family":"Kazama","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Fukushima Medical University , Fukushima 960-1295,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences , Niigata 951-8510,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"4","key":"2025091916230630100_ref1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ekir.2024.01.002","article-title":"Alkaline phosphatase and parathyroid hormone levels: international variation and associations with clinical outcomes in the DOPPS","volume":"9","author":"Yamamoto","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"26","key":"2025091916230630100_ref2","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Investigators","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2025091916230630100_ref3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"2025091916230630100_ref4","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.ekir.2020.09.010","article-title":"A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET trial)","volume":"5","author":"Itano","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2025091916230630100_ref5","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1038\/s41598-019-42017-z","article-title":"Long-term efficacy and safety of evocalcet in Japanese patients with secondary hyperparathyroidism receiving hemodialysis","volume":"9","author":"Yokoyama","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"2025091916230630100_ref6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","article-title":"Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis","volume":"76","author":"Palmer","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2025091916230630100_ref7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s00774-024-01500-y","article-title":"Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials","volume":"42","author":"Wakamatsu","year":"2024","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"2025091916230630100_ref8","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.kint.2018.12.015","article-title":"Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration","volume":"95","author":"Diaz-Tocados","year":"2019","journal-title":"Kidney Int"},{"issue":"21","key":"2025091916230630100_ref9","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1111\/bph.14344","article-title":"Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity","volume":"175","author":"Diepenhorst","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2025091916230630100_ref10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12882-021-02482-z","article-title":"Bone responsiveness to parathyroid hormone is negatively associated with parathyroid hormone-lowering drug use in patients undergoing hemodialysis: a cross-sectional study","volume":"22","author":"Tominaga","year":"2021","journal-title":"BMC Nephrol"},{"issue":"6","key":"2025091916230630100_ref11","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.kint.2016.06.041","article-title":"Parathyroid hormone metabolism and signaling in health and chronic kidney disease","volume":"90","author":"Evenepoel","year":"2016","journal-title":"Kidney Int"},{"issue":"10","key":"2025091916230630100_ref12","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2215\/CJN.0000000000000253","article-title":"Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism: a randomized placebo-controlled trial","volume":"18","author":"Shigematsu","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2025091916230630100_ref13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","article-title":"Changing bone patterns with progression of chronic kidney disease","volume":"89","author":"Drueke","year":"2016","journal-title":"Kidney Int"},{"issue":"5","key":"2025091916230630100_ref14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40620-017-0406-x","article-title":"Uremic toxicity and bone in CKD","volume":"30","author":"Yamamoto","year":"2017","journal-title":"J Nephrol"},{"issue":"5","key":"2025091916230630100_ref15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.ajkd.2021.07.027","article-title":"Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy","volume":"79","author":"Jorgensen","year":"2022","journal-title":"Am J kidney Dis"},{"issue":"12","key":"2025091916230630100_ref16","doi-asserted-by":"publisher","first-page":"e4350","DOI":"10.1210\/clinem\/dgac522","article-title":"Lower bone turnover and skeletal PTH responsiveness in Japanese compared to European patients on hemodialysis","volume":"107","author":"Evenepoel","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"33","key":"2025091916230630100_ref17","doi-asserted-by":"publisher","first-page":"30337","DOI":"10.1074\/jbc.M201804200","article-title":"Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D","volume":"277","author":"Canaff","year":"2002","journal-title":"J Biol Chem"},{"issue":"12","key":"2025091916230630100_ref18","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1093\/ckj\/sfad213","article-title":"Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study","volume":"16","author":"Inaguma","year":"2023","journal-title":"Clin Kidney J"},{"issue":"11","key":"2025091916230630100_ref19","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1002\/jbmr.126","article-title":"Increased osteocyte death and mineralization inside bone after parathyroidectomy in patients with secondary hyperparathyroidism","volume":"25","author":"Yajima","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"04","key":"2025091916230630100_ref20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5414\/CNP69269","article-title":"An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism","volume":"69","author":"Malluche","year":"2008","journal-title":"Clin Nephrol"},{"issue":"suppl 1","key":"2025091916230630100_ref21","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1111\/j.1744-9987.2008.00630.x","article-title":"Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism","volume":"12","author":"Yajima","year":"2008","journal-title":"Ther Apher Dial"},{"issue":"11","key":"2025091916230630100_ref22","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.2215\/CJN.0000000000000254","article-title":"Changes in bone quality after treatment with Etelcalcetide","volume":"18","author":"Khairallah","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2025091916230630100_ref23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.kint.2020.04.013","article-title":"Clinical evidence of direct bone effects of cinacalcet","volume":"98","author":"Jorgensen","year":"2020","journal-title":"Kidney Int"},{"issue":"3","key":"2025091916230630100_ref24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"Fukagawa","year":"2013","journal-title":"Ther Apher Dial"},{"issue":"1","key":"2025091916230630100_ref25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfr317","article-title":"Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study","volume":"27","author":"Iimori","year":"2012","journal-title":"Nephrol Dial Transplant"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf139\/64147480\/ziaf139.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/10\/ziaf139\/64147480\/ziaf139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/10\/ziaf139\/64147480\/ziaf139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T20:23:16Z","timestamp":1758313396000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf139\/8242508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf139","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,28]]},"article-number":"ziaf139"}}